SLCO1A2

Across TCGA pan-cancer cohorts, SLCO1A2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLCO1A2 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLCO1A2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLCO1A2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where SLCO1A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.852	0.332	.002	30	view →
HNSC	DFS	Median	All	0.551	0.746	.019	12	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
LSCC	DFS	Tertile	All	0.988	0.434	.006	6	view →
GBM	OS	Median	All	0.553	0.249	.016	2	view →
CCRCC	OS	Median	II,III,IV	1.000	0.554	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLCO1A2–LUAD (DFS)

Open the LUAD breakdown →